Guaifenesin 40 mg/ML Oral Solution [Diabetic Tussin Mucus Relief]
RxNorm 1086004

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1086004 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: guaifenesin 40 mg/ML Oral Solution [Diabetic Tussin Mucus Relief].

The following semantic concepts and normalized strings are associated with this clinical entity:

SY
Diabetic Tussin Mucus Relief 40 mg/ML Oral Solution
AUI:3607476
View
SBD
Guaifenesin 40 mg/ML Oral Solution [Diabetic Tussin Mucus Relief]
AUI:12367668
View
TMSY
GuaiFENesin 40 mg/ML Oral Solution [Diabetic Tussin Mucus Relief]
AUI:3732275
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SY

Synonym (SY):
Diabetic Tussin Mucus Relief 40 mg/ML Oral Solution
(Atom ID: 3607476)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Diabetic Tussin Mucus Relief 40 MG/ML Oral Solution
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1086004
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
3607476
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1086004
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SBD

Semantic Branded Drug (SBD):
Guaifenesin 40 mg/ML Oral Solution [Diabetic Tussin Mucus Relief]
(Atom ID: 12367668)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
guaifenesin 40 MG/ML Oral Solution [Diabetic Tussin Mucus Relief]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1086004
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12367668
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
1086004
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{316014} 5032
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{316014} 5032
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{316014} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN OBSOLETED
04/30/2020
Date the RxNorm atom became obsolete
RXTERM FORM
Sol
The RxTerm dose form name for this drug
TMSY

Tall Man Lettering Synonym (TMSY):
GuaiFENesin 40 mg/ML Oral Solution [Diabetic Tussin Mucus Relief]
(Atom ID: 3732275)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
guaiFENesin 40 MG/ML Oral Solution [Diabetic Tussin Mucus Relief]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
O
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1086004
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
3732275
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
TMSY
Tall Man Lettering Synonym (Tall Man Lettering synonym of another TTY, given to distinguish between commonly confused drugs.)
Source Code
1086004
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.